File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension

TitleBosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension
Authors
Issue Date2007
PublisherSage Publications Ltd. The Journal's web site is located at http://lup.sagepub.com
Citation
Lupus, 2007, v. 16 n. 4, p. 279-285 How to Cite?
Abstract
Pulmonary arterial hypertension (PAH) in patients with systemic lupus erythematosus (SLE) is uncommon but is associated with poor survival. This study aimed to examine the long-term effects of bosentan, a dual endothelin-1 receptor antagonist, on symptomatology, haemodynamics and quality of life measures in SLE patients with symptomatic PAH. Four local patients had been followed up prospectively with pre-defined protocol during 12-months of bosentan treatment. Six minute walk distance (6MWD), NYHA functional class, Borg Dyspnoea Index (BDI) and SF-36 were measured at 0, 3, 6, 9 and 12 months. Systolic pulmonary arterial pressure (PAP) was measured by transthoracic echocardiography at zero, six and 12 months. Clinical parameters were analysed, pooling data from other SLE patients reported in the literature (n = 4). Bosentan was found to result in significant improvement in 6MWD compared to baseline [+24.8 m, +26.2 m, +54 m and +62.7 m at three (P = 0.001), six (P = 0.001), nine (P = 0.24) and 12 (P = 0.01) months respectively]. A differential effect was found with greater response in patients with lower exercise capacity. This was accompanied by decrease in NYHA functional class, BDI, transient or sustained drop in systolic PAP and mild improvement in SF-36 domains including mental health, vitality, social function and general health. Significantly deranged liver function was found in one patient. © 2007 SAGE Publications.
Persistent Identifierhttp://hdl.handle.net/10722/77631
ISSN
2013 Impact Factor: 2.481
ISI Accession Number ID
References

 

Author Affiliations
  1. Queen Mary Hospital Hong Kong
DC FieldValueLanguage
dc.contributor.authorMok, MYen_HK
dc.contributor.authorTsang, PLen_HK
dc.contributor.authorLam, YMen_HK
dc.contributor.authorLo, Yen_HK
dc.contributor.authorWong, WSen_HK
dc.contributor.authorLau, CSen_HK
dc.date.accessioned2010-09-06T07:34:00Z-
dc.date.available2010-09-06T07:34:00Z-
dc.date.issued2007en_HK
dc.identifier.citationLupus, 2007, v. 16 n. 4, p. 279-285en_HK
dc.identifier.issn0961-2033en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77631-
dc.description.abstractPulmonary arterial hypertension (PAH) in patients with systemic lupus erythematosus (SLE) is uncommon but is associated with poor survival. This study aimed to examine the long-term effects of bosentan, a dual endothelin-1 receptor antagonist, on symptomatology, haemodynamics and quality of life measures in SLE patients with symptomatic PAH. Four local patients had been followed up prospectively with pre-defined protocol during 12-months of bosentan treatment. Six minute walk distance (6MWD), NYHA functional class, Borg Dyspnoea Index (BDI) and SF-36 were measured at 0, 3, 6, 9 and 12 months. Systolic pulmonary arterial pressure (PAP) was measured by transthoracic echocardiography at zero, six and 12 months. Clinical parameters were analysed, pooling data from other SLE patients reported in the literature (n = 4). Bosentan was found to result in significant improvement in 6MWD compared to baseline [+24.8 m, +26.2 m, +54 m and +62.7 m at three (P = 0.001), six (P = 0.001), nine (P = 0.24) and 12 (P = 0.01) months respectively]. A differential effect was found with greater response in patients with lower exercise capacity. This was accompanied by decrease in NYHA functional class, BDI, transient or sustained drop in systolic PAP and mild improvement in SF-36 domains including mental health, vitality, social function and general health. Significantly deranged liver function was found in one patient. © 2007 SAGE Publications.en_HK
dc.languageengen_HK
dc.publisherSage Publications Ltd. The Journal's web site is located at http://lup.sagepub.comen_HK
dc.relation.ispartofLupusen_HK
dc.rightsLupus. Copyright © Sage Publications Ltd.en_HK
dc.subject.meshAdulten_HK
dc.subject.meshAntihypertensive Agents - therapeutic useen_HK
dc.subject.meshBlood Pressure - drug effectsen_HK
dc.subject.meshExercise Toleranceen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshHypertension, Pulmonary - complications - drug therapyen_HK
dc.subject.meshLupus Erythematosus, Systemic - complicationsen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshQuality of Lifeen_HK
dc.subject.meshSeverity of Illness Indexen_HK
dc.subject.meshSulfonamides - therapeutic useen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleBosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertensionen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0961-2033&volume=16&issue=4&spage=279&epage=285&date=2007&atitle=Bosentan+Use+in+Systemic+Lupus+Erythematosus+Patients+with+Pulmonary+Arterial+Hypertensionen_HK
dc.identifier.emailMok, MY:temy@hkucc.hku.hken_HK
dc.identifier.emailLau, CS:cslau@hku.hken_HK
dc.identifier.authorityMok, MY=rp00490en_HK
dc.identifier.authorityLau, CS=rp01348en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1177/0961203307076509en_HK
dc.identifier.pmid17439935en_HK
dc.identifier.scopuseid_2-s2.0-34249015268en_HK
dc.identifier.hkuros134353en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34249015268&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume16en_HK
dc.identifier.issue4en_HK
dc.identifier.spage279en_HK
dc.identifier.epage285en_HK
dc.identifier.isiWOS:000246669200007-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridMok, MY=7006024184en_HK
dc.identifier.scopusauthoridTsang, PL=16318053100en_HK
dc.identifier.scopusauthoridLam, YM=35316083700en_HK
dc.identifier.scopusauthoridLo, Y=35148230000en_HK
dc.identifier.scopusauthoridWong, WS=8737892100en_HK
dc.identifier.scopusauthoridLau, CS=14035682100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats